Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia

Xin, Baozhong; Platzer, Petra; Fink, Stephen P.; Reese, Lisa; Nosrati, Arman; Willson, James K.V.; Wilson, Keith E.; Markowitz, Sanford D.

doi:10.1038/sj.onc.1208134

Cited by 22 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to primary genetic alterations, the cancer phenotype is also importantly modulated by down stream alterations in the levels of expression of different effector genes (2–4). Expression microarrays enable comprehensive profiling of the cancer transcriptome and identification of cancer specific changes in gene expression (5, 6). …”

Section: Introductionmentioning

confidence: 99%

Ugene, a Newly Identified Protein That Is Commonly Overexpressed in Cancer and Binds Uracil DNA Glycosylase

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Ugene, a Newly Identified Protein That Is Commonly Overexpressed in Cancer and Binds Uracil DNA Glycosylase

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…The transcripts of 14 genes were identified as being correlated with the incidence of tumor tissues and were associated with clinical outcomes in a microarray study [21] . Two genes with elevated expression in colon cancer patients [22][23] , encoding the A3 adenosine receptor and CCSP-2, were also assayed at the beginning of our study. Since the measurement of a higher cycle number (i.e., Ct greater than 30) generally implies lower amplification efficiency [24] , 15 genes were used for further analysis (Table 2) after eliminating genes with low amplification efficiencies.…”

Section: Quantitative Real-time Polymerase Chain Reactionmentioning

confidence: 99%

A Gene Expression Profile of Peripheral Blood in Colorectal Cancer

Huang¹,

Terng²

2014

JMBT

View full text Add to dashboard Cite

AIM: Optimal molecular markers for detecting colorectal cancer (CRC) in a blood-based assay were evaluated. METHODS:A matched (by variables of age and sex) case-control design (111 CRC and 227 non-cancer samples) was applied. Total RNAs isolated from the 338 blood samples were reverse-transcribed, and the relative transcript levels of candidate genes were analyzed. The training set was made of 162 random samples of the total 338 samples. A logistic regression analysis was performed, and odds ratios for each gene were determined between CRC and non-cancer. The samples (n = 176) in the testing set were used to validate the logistic model, and an inferred performance (generality) was verified. By pooling 12 public microarray datasets (GSE 4107, 4183, 8671, 9348, 10961, 13067, 13294, 13471, 14333, 15960, 17538, and 18105), which included 519 cases of adenocarcinoma and 88 controls of normal mucosa, we were able to verify the selected genes from logistic models and estimate their external generality. RESULTS:The logistic regression analysis resulted in the selection of five significant genes (P < 0.05; MDM2 , DUSP6 , CPEB4 , MMD , and EIF2S3 ), with odds ratios of 2.978, 6.029, 3.776, 0.538 and 0.138, respectively. The five-gene model performed stably for the discrimination of CRC cases from controls in the training set, with accuracies ranging from 73.9% to 87.0%, a sensitivity of 95% and a specificity of 95%. In addition, a good performance in the test set was obtained using the discrimination model, providing 83.5% ac- = 0.853, AUC = 0.978, accuracy = 0.949, specificity = 0.818 and sensitivity = 0.971). RETROSPECTIVE STUDY

show abstract

“…This approach has, however, not been evaluated as a noninvasive screening tool, and it is therefore considered investigational [49,50]. Currently, the markers most often elevated in advanced CRC are carcinoembryonic antigen (CEA) [51] and the carbohydrate antigen, which is also called cancer antigen (CA) 19-9 [52], but neither of these markers has been found to be a useful, or a reliable diagnostic screen for colorectal cancer.…”

Section: Current Methods For Colon Cancer Screeningmentioning

confidence: 99%

MicroRNAs as molecular markers for colon cancer Diagnostic screening in stool & blood

Ahmed¹,

Ahmed²

2017

Med Res Innov

View full text Add to dashboard Cite

Screening for colon cancer (CC) allows for diagnosis of the early stage for malignancy and potentially reduces disease mortality as the cancer could be cured at disease earliest stages. Early detection could be desirable if accurate, practical and cost effective diagnostic measures for this cancer are available. Mortality and morbidity from colon cancer represent a major health problem involving a malignant disease that is theoretically preventable through screening. Current screening methods (e.g., the immunological fecal occult blood test, FOBTi, obtained from patients' medical records) either lacks sensitivity and requires dietary restriction, which impedes compliance and use; are costly (e.g., colonoscopy), which decreases compliance; or could lead to mortality. In comparison to the FOBT test, a noninvasive sensitive screen for which there is no requirement for dietary restriction would be a more convenient test. Colorectal cancer (CRC) is the only cancer for which screening by colonoscopy is recommended. Although colonoscopy is a reliable screening tool, its invasive nature, accompanying abdominal pain, potential complications and high cost have hampered the application of this screening method worldwide.A novel screening approach using the stable miRNA molecules, which are relatively nondegradable when extracted from noninvasive stool and semi-invasive blood samples by currently available commercial kits and manipulated thereafter, would be preferable to a transcriptomic messenger (m)RNA-, a mutation DNA-, an epigenetic-or a proteomic-based test. The approach utilizes reverse transcriptase (RT), followed by a modified quantitative real-time polymerase chain reaction (qPCR). Although exosomal RNA would not be measured, using a restricted extraction of total RNA from stool or blood, then a parallel test could also be carried out on RNA obtained from stool or plasma samples, and appropriate corrections for exsosomal loss can be made to obtain accurate and quantitative results. Eventually, a chip would be developed to facilitate diagnosis, as has been carried out for the quantification of genetically modified organisms (GMOs) in foods. The gold standard to which the molecular miRNA test is compared is colonoscopy. If performance criteria are met, as detailed herein, then a miRNA test in human stool or blood samples based on high throughput automated technologies and quantitative expression measurements --commonly used in the diagnostic clinical laboratory--would eventually be advanced to the clinical setting, which will make a vivid impact on the prevention of colon cancer.Correspondence to: Farid E. Ahmed, GEM

show abstract

Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia

Cited by 22 publications

References 17 publications

Ugene, a Newly Identified Protein That Is Commonly Overexpressed in Cancer and Binds Uracil DNA Glycosylase

Ugene, a Newly Identified Protein That Is Commonly Overexpressed in Cancer and Binds Uracil DNA Glycosylase

A Gene Expression Profile of Peripheral Blood in Colorectal Cancer

MicroRNAs as molecular markers for colon cancer Diagnostic screening in stool & blood

Contact Info

Product

Resources

About